Why is this ASX All Ords biotech share crashing 12% today?

This biotech is having a day to forget on Tuesday…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day.

In afternoon trade, the biotechnology company's shares are down 12% to $1.48.

This makes the Paradigm share price one of the worst performers on the All Ordinaries index today.

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

Why is the Paradigm share price sinking?

Investors have been hitting the sell button on Tuesday after Paradigm announced the surprise exit of its CEO and managing director, Marco Polizzi.

According to the release, Mr Polizzi has stepped down from his role immediately and will cease employment with the company on 20 February.

Paradigm only announced the appointment of Polizzi at the end of May, with the experienced pharmaceutical industry executive commencing in the role on 1 July. At the time, the company hyped up his appointment, describing him as "a CEO with the skills to fully unlock the commercial value of the company."

No reason was given for the CEO's exit after just a few months with the company. Nor did Polizzi leave a parting comment, which is never a good look and could potentially be an indication of boardroom tensions.

What now?

The Paradigm board has acted quickly and appointed the company's founder and non-executive chairman Paul Rennie as its new leader. He said:

I am pleased to advise that the personal circumstances that originally required my stepping down from the Managing Director role in 2021, have now been successfully resolved. I look forward to working closely again with the Paradigm executive team and the Board in continuing our journey together.

Following today's decline, the Paradigm share price has now lost almost a third of its value over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

This ASX healthcare stock could more than double according to Canaccord Genuity

It's shaping up as a big year for this drug developer.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Broker Notes

Why beaten down CSL shares now offer 'long-term appeal'

A leading expert gives his outlook for CSL’s beaten down shares.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

Why Neuren shares are rebounding on Wednesday after a brutal 2026 sell-off

Neuren shares jump after DAYBUE STIX expands across the US.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

After a 30% 2026 slide, Pro Medicus shares are rocketing again

Pro Medicus shares jump after another major contract win.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Healthcare Shares

Could the CSL share price reach $200 in 2026?

The biotech's shares have had a tough run, but the long-term story may not be broken.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Pro Medicus announces $23m US contract

Pro Medicus has signed a $23 million, five-year cloud imaging contract with University of Maryland Medical System.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

2 classy ASX healthcare stocks to buy before the next market surge

If sentiment shifts, these global powerhouses could lead the rally.

Read more »

Two people jump and high five above a city skyline.
Healthcare Shares

Why rebounding Telix shares could still rise 40%

Bell Potter doesn't think it is too late to buy this stock.

Read more »